<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2960214-A1" country="EP" doc-number="2960214" kind="A1" date="20151230" family-id="44259898" file-reference-id="261542" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160452466" ucid="EP-2960214-A1"><document-id><country>EP</country><doc-number>2960214</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12777603-A" is-representative="YES"><document-id mxw-id="PAPP193867900" load-source="docdb" format="epo"><country>EP</country><doc-number>12777603</doc-number><kind>A</kind><date>20120424</date><lang>ES</lang></document-id><document-id mxw-id="PAPP193867901" load-source="patent-office" format="original"><country>EP</country><doc-number>12777603.7</doc-number><date>20120424</date><lang>ES</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162035231" ucid="ES-201130652-A" load-source="docdb"><document-id format="epo"><country>ES</country><doc-number>201130652</doc-number><kind>A</kind><date>20110426</date></document-id></priority-claim><priority-claim mxw-id="PPC162027114" ucid="ES-2012070274-W" load-source="docdb"><document-id format="epo"><country>ES</country><doc-number>2012070274</doc-number><kind>W</kind><date>20120424</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1953498980" load-source="ipcr">C02F   3/12        20060101ALI20160401BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1953500602" load-source="ipcr">C02F   1/28        20060101ALI20160401BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1953501790" load-source="ipcr">C02F 103/34        20060101ALN20160401BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1953503009" load-source="ipcr">B01D  61/14        20060101ALI20160401BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1953503783" load-source="ipcr">C02F   9/14        20060101AFI20160401BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1953505000" load-source="ipcr">C02F 103/36        20060101ALN20160401BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1987770398" load-source="docdb" scheme="CPC">C02F2103/343       20130101 LA20131011BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987772583" load-source="docdb" scheme="CPC">C02F   3/1263      20130101 LA20130930BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987776305" load-source="docdb" scheme="CPC">C02F   3/1273      20130101 LI20131011BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987778043" load-source="docdb" scheme="CPC">C02F   3/1226      20130101 FI20131011BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987782904" load-source="docdb" scheme="CPC">B01D  61/145       20130101 LI20131011BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987785279" load-source="docdb" scheme="CPC">Y02W  10/15        20150501 LA20150515BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165548864" lang="DE" load-source="patent-office">VERFAHREN ZUR ENTFERNUNG VON PHARMAZEUTISCHEN PRODUKTEN AUS ABWASSER</invention-title><invention-title mxw-id="PT165548865" lang="EN" load-source="patent-office">METHOD FOR ELIMINATING PHARMACEUTICAL PRODUCTS FROM WASTE WATER</invention-title><invention-title mxw-id="PT165548866" lang="FR" load-source="patent-office">PROCÉDÉ D'ÉLIMINATION DE PRODUITS PHARMACEUTIQUES PRÉSENTS DANS DES EAUX USÉES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103317594" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>UNIV SANTIAGO COMPOSTELA</last-name><address><country>ES</country></address></addressbook></applicant><applicant mxw-id="PPAR1103317945" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>UNIVERSIDADE DE SANTIAGO DE COMPOSTELA</last-name></addressbook></applicant><applicant mxw-id="PPAR1101643515" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Universidade de Santiago de Compostela</last-name><iid>101344138</iid><address><street>Área de Valorización Transferencia e Emprendemento Edificio Emprendia Campus Vida</street><city>15782 Santiago de Compostela</city><country>ES</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103322083" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>OMIL PRIETO FRANCISCO</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103308690" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>OMIL PRIETO, FRANCISCO</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649389" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>OMIL PRIETO, FRANCISCO</last-name><address><street>Universidade de Santiago de Compostela Área de Valorización Transferencia e Emprendemento Edificio EMPRENDIA Campus Vida</street><city>E-15782 Santiago de Compostela</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103328971" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>SERRANO PALACIOS DENISSE</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103309564" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>SERRANO PALACIOS, DENISSE</last-name></addressbook></inventor><inventor mxw-id="PPAR1101648549" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>SERRANO PALACIOS, DENISSE</last-name><address><street>Universidade de Santiago de Compostela Área de Valorización Transferencia e Emprendemento Edificio EMPRENDIA Campus Vida</street><city>E-15782 Santiago de Compostela</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103323494" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>SUÁREZ MARTÍNEZ SONIA</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103326520" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>SUÁREZ MARTÍNEZ, Sonia</last-name></addressbook></inventor><inventor mxw-id="PPAR1101649464" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>SUÁREZ MARTÍNEZ, Sonia</last-name><address><street>Universidade de Santiago de Compostela Área de Valorización Transferencia e Emprendemento Edificio EMPRENDIA Campus Vida</street><city>E-15782 Santiago de Compostela</city><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103304662" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>LEMA RODICIO JUAN M</last-name><address><country>ES</country></address></addressbook></inventor><inventor mxw-id="PPAR1103319392" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>LEMA RODICIO, JUAN M.</last-name></addressbook></inventor><inventor mxw-id="PPAR1101644678" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>LEMA RODICIO, JUAN M.</last-name><address><street>Universidade de Santiago de Compostela Área de Valorización Transferencia e Emprendemento Edificio EMPRENDIA Campus Vida</street><city>E-15782 Santiago de Compostela</city><country>ES</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101645425" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Sugrañes Patentes y Marcas</last-name><iid>100060808</iid><address><street>Calle Provenza 304</street><city>08008 Barcelona</city><country>ES</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="ES-2012070274-W"><document-id><country>ES</country><doc-number>2012070274</doc-number><kind>W</kind><date>20120424</date><lang>ES</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012146815-A1"><document-id><country>WO</country><doc-number>2012146815</doc-number><kind>A1</kind><date>20121101</date><lang>ES</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660624045" load-source="docdb">AL</country><country mxw-id="DS660788414" load-source="docdb">AT</country><country mxw-id="DS660624046" load-source="docdb">BE</country><country mxw-id="DS660624522" load-source="docdb">BG</country><country mxw-id="DS660722550" load-source="docdb">CH</country><country mxw-id="DS660622974" load-source="docdb">CY</country><country mxw-id="DS660788415" load-source="docdb">CZ</country><country mxw-id="DS660624051" load-source="docdb">DE</country><country mxw-id="DS660622983" load-source="docdb">DK</country><country mxw-id="DS660622984" load-source="docdb">EE</country><country mxw-id="DS660701952" load-source="docdb">ES</country><country mxw-id="DS660624527" load-source="docdb">FI</country><country mxw-id="DS660702403" load-source="docdb">FR</country><country mxw-id="DS660624052" load-source="docdb">GB</country><country mxw-id="DS660622985" load-source="docdb">GR</country><country mxw-id="DS660624053" load-source="docdb">HR</country><country mxw-id="DS660788416" load-source="docdb">HU</country><country mxw-id="DS660722571" load-source="docdb">IE</country><country mxw-id="DS660622986" load-source="docdb">IS</country><country mxw-id="DS660702404" load-source="docdb">IT</country><country mxw-id="DS660622999" load-source="docdb">LI</country><country mxw-id="DS660624528" load-source="docdb">LT</country><country mxw-id="DS660708519" load-source="docdb">LU</country><country mxw-id="DS660624529" load-source="docdb">LV</country><country mxw-id="DS660624530" load-source="docdb">MC</country><country mxw-id="DS660708520" load-source="docdb">MK</country><country mxw-id="DS660708521" load-source="docdb">MT</country><country mxw-id="DS660788417" load-source="docdb">NL</country><country mxw-id="DS660624054" load-source="docdb">NO</country><country mxw-id="DS660623000" load-source="docdb">PL</country><country mxw-id="DS660624535" load-source="docdb">PT</country><country mxw-id="DS660788418" load-source="docdb">RO</country><country mxw-id="DS660624536" load-source="docdb">RS</country><country mxw-id="DS660623001" load-source="docdb">SE</country><country mxw-id="DS660702405" load-source="docdb">SI</country><country mxw-id="DS660624063" load-source="docdb">SK</country><country mxw-id="DS660623002" load-source="docdb">SM</country><country mxw-id="DS660708522" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA166480780" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The invention relates to a process for the removal of pharmaceutical products present in wastewater by means of using powdered activated carbon (PAC) in a sequential bioreactor coupled with a chamber with an ultrafiltration membrane. This process comprises a first reaction unit which operates in a sequential manner, where the PAC is directly added. The effluent generated from this first unit passes into a contiguous chamber having an ultrafiltration membrane with a pore size in the range of 0.04-0.4 µm, provided with continuous aeration and where the permeate is generated, which constitutes the final effluentof the process. The PAC is added for the purpose of maximizing the removal of pharmaceutical pollutants, especially those which are more recalcitrant. By means of this process, it is possible to not only reduce the organic matter (&gt;95%) and nutrients (&gt;75%), but to also achieve high efficiency (&gt;90%) in the removal of pharmaceutical products present in trace amounts (&lt;100 µg/L).<img id="iaf01" file="imgaf001.tif" wi="85" he="64" img-content="drawing" img-format="tif"/></p></abstract><abstract mxw-id="PA166760592" lang="EN" source="EPO" load-source="docdb"><p>The invention relates to a process for the removal of pharmaceutical products present in wastewater by means of using powdered activated carbon (PAC) in a sequential bioreactor coupled with a chamber with an ultrafiltration membrane. This process comprises a first reaction unit which operates in a sequential manner, where the PAC is directly added. The effluent generated from this first unit passes into a contiguous chamber having an ultrafiltration membrane with a pore size in the range of 0.04-0.4 µm, provided with continuous aeration and where the permeate is generated, which constitutes the final effluentof the process. The PAC is added for the purpose of maximizing the removal of pharmaceutical pollutants, especially those which are more recalcitrant. By means of this process, it is possible to not only reduce the organic matter (&gt;95%) and nutrients (&gt;75%), but to also achieve high efficiency (&gt;90%) in the removal of pharmaceutical products present in trace amounts (&lt;100 µg/L).</p></abstract><description mxw-id="PDES98405481" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b><u>Technical Field of the Invention</u></b></heading><p id="p0001" num="0001">The present invention relates to a process for the removal of contaminating pharmaceutical products present in wastewater in trace concentrations by means of adding powdered activated carbon in a sequential bioreactor coupled to a contiguous chamber containing an ultrafiltration membrane.</p><heading id="h0002"><b><u>State of the Art</u></b></heading><p id="p0002" num="0002">Pharmaceutical compounds are a group of organic pollutants with a large number of active ingredients that are consumed on a massive scale in developed societies. These substances are used in the formulation of pharmacological products as well as personal care products (shampoos, body lotions, sunscreens, etc.), therefore covering a wide spectrum concerning the molecular structure, physicochemical properties, biodegradability potential and persistence. Thousands of active ingredients are being used today for synthesizing an even larger number of products. Taking the scope of the EU as an example, more than 3000 different substances are being used in human medicine alone, to which a very significant number of drugs for veterinary use must be added. In terms of the prospects for upcoming years, an increase in medicament consumption is envisaged primarily due to gradual population aging, although it may also be due to the improvement in the quality of life. Legislative regulation of these substances in the environment is imminent, as indicated in the Water Framework Directive (2000/60/EC). In this sense, a list of priority pollutants is updated every four years which already includes several pharmaceutical compounds.</p><p id="p0003" num="0003">These compounds have been detected in different environmental compartments, such as rivers, lakes, groundwater, sediments, etc. The lack of conclusive information about the potential ecotoxicological impact derived from the presence of such compounds in the environment has turned this subject into a key issue in the water treatment sector. The growing concern is based<!-- EPO <DP n="2"> --> fundamentally on the fact that such substances have been specifically designed to produce a biological effect in patients to whom the substances are administered, even at very low concentrations.</p><p id="p0004" num="0004">The pharmaceutical compounds found in the environment come from several sources such as oral consumption, which entails urine and fecal excretion of the non-metabolized fraction of the medicament, or the washing of substances that are applied on the skin (fragrances, lotions, etc.), thus being present in domestic wastewater and reaching the Wastewater Treatment Plant (WWTP). Furthermore, hospitals are characterized by a high consumption of such substances, which means that wastewater from hospitals has a higher load of these compounds than urban wastewater (UW). Besides having very high water consumption, hospitals generally discharge very complex water due to the wide range of compounds used (diagnostic agents such as contrast medium, anesthetics such as alkylphenols, disinfectants such as alcohols, formaldehyde and chlorophenols, drugs, etc.). In a study conducted by this research group from Universidade de Santiago de Compostela, it was found that the hospital effluents have contamination levels that are significantly higher than municipal effluents, with maximum concentrations measured for conventional parameters that tripled the standards set for concentrated municipal wastewater. Concentrations in hospital effluents of up to 40 times those detected in municipal water were measured for some pharmaceutical products (<nplcit id="ncit0001" npl-type="s"><text>Suárez S. 2008, PhD Dissertation, Universidade de Santiago de Composte</text></nplcit>la).</p><p id="p0005" num="0005">With the technology implemented in the more modern WWTPs, an effective removal of carbon and nitrogen present in the UW, in addition to strict microbiological control, is assured. However, these facilities are receiving a large number of organic micro-pollutants, such as pharmaceutical products, for which conventional treatment technologies have not been specifically designed. This leads to an uncontrolled discharge of pharmaceutical products into surface and groundwater bodies with the subsequent impact on the environment.</p><p id="p0006" num="0006">Pharmaceutical products are eliminated during wastewater treatment by means of a set of mechanisms, such as volatilization, adsorption on sludge and biological and/or chemical transformation. Parameters such as temperature, the use of additives, Solids Retention Time (SRT) and biomass composition, structure and concentration, have shown to significantly influence the efficiency in<!-- EPO <DP n="3"> --> eliminating these compounds (<nplcit id="ncit0002" npl-type="b"><text>Omil F et al., 2010, In: Xenobiotics in the Urban Water Cycle, Ed. Springer, pp. 283-306</text></nplcit>). In summary, operating with high sludge concentrations and long SRTs are favorable for maximizing the removal of pharmaceutical products.</p><p id="p0007" num="0007">On the other hand, it has been observed that operating under nitrification-denitrification conditions results in the generation of ammonia monooxygenase (AMO) enzyme by specific groups of bacteria improving the removal of some pharmaceutical pollutants, like naproxen, roxithromycin and erythromycin, iopromide and trimethoprim (<nplcit id="ncit0003" npl-type="s"><text>Suárez et al., 2010, Water Research 44, pp. 3214-3224</text></nplcit>; <nplcit id="ncit0004" npl-type="s"><text>Batt et al., 2006, Environ. Sci. Technol. 40, pp. 7367-7373</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>Pérez et al., 2005, Environmental Toxicology and Chemistry 24, pp. 1361-1367</text></nplcit>) or even with the synthetic hormone ethinylestradiol (<nplcit id="ncit0006" npl-type="s"><text>Forrez et al., 2008; Journal of Chemical Technology and Biotechnology 84, pp. 119-125</text></nplcit>).</p><p id="p0008" num="0008">Membrane bioreactors are based on a combination of a bioreactor with biomass in suspension in which a microfiltration or ultrafiltration membrane is submerged or placed externally. It has the advantage of favoring the operation with high sludge concentrations and long SRTs compared with conventional activated sludge (CAS) systems and of producing high quality effluents in terms of their microbiological characteristics and conventional parameters (fundamentally solids). However, it has been observed that pharmaceutical products are not eliminated through size exclusion in the membrane filtration step, so it remains unclear if such systems can improve the removal of these compounds in trace amounts. This means that such systems favor the removal of biodegradable pharmaceutical products (e.g., ibuprofen) and also of those products having the tendency to be sorbed on the sludge (e.g., galaxolide). However, some compounds that have been found to be highly persistent in CAS systems (e.g. carbamazepine) are not eliminated in membrane bioreactors either (<nplcit id="ncit0007" npl-type="s"><text>Clara M et al., 2004, Water Research 38, pp. 947-954</text></nplcit>).</p><p id="p0009" num="0009">It has been demonstrated that the use of activated carbon in adsorption columns as a tertiary treatment is effective for the removal of pharmaceutical compounds (<nplcit id="ncit0008" npl-type="s"><text>Choubert JM et al., 2011, Water Science &amp; Technology 63, pp. 57-65</text></nplcit>). However, the addition of activated carbon directly in wastewater treatment plants for the purpose of eliminating pharmaceutical pollutants is not a known strategy. Nevertheless, there are some works in activated sludge systems in<!-- EPO <DP n="4"> --> which powdered activated carbon at concentrations of 500 to 4000 mg/L has been used to increase the efficacy of the nitrification step (<nplcit id="ncit0009" npl-type="s"><text>Ng and Stenstrom, 1987, J. Environ. Eng. 113, pp. 1285-1301</text></nplcit>), whereas other authors have observed an increase in the removal of organic matter as well as a significant decrease in toxicity caused by inhibitory compounds (<nplcit id="ncit0010" npl-type="s"><text>Widjaja T. et al., 2004, Chemosphere 57, pp. 1219-1224</text></nplcit>). Furthermore, it has been observed that activated carbon is a suitable support to which bacteria can adhere, improving the retention of those slow-growing bacteria, such as nitrifying bacteria (<nplcit id="ncit0011" npl-type="s"><text>Thuy and Visvanathan, 2006, Water Science and Technology 53, pp. 89-97</text></nplcit>). More recent research has demonstrated that the use of activated carbon can be suitable for minimizing the problems of fouling typically occurring in membrane bioreactors (MBRs). In this sense, concentrations of 0.5 to 3 g/L have been used in the MBR aeration tank to prevent and control membrane fouling (<nplcit id="ncit0012" npl-type="s"><text>Remy M et al., 2009, Water Research 43, pp. 345-350</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Munz G et al., 2007, Desalination 207, pp. 349-360</text></nplcit>).</p><p id="p0010" num="0010">In the present invention, the process proposes using a sequential bioreactor operated under nitrification-denitrification conditions in the presence of PAC, coupled to a chamber containing an ultrafiltration membrane which, as a whole, entails a very efficient process for the removal of pharmaceutical compounds. The removal of those compounds that are more biodegradable is favored by operating under nitrification-denitrification conditions, with high biomass concentrations and long SRTs, whereas the presence of PAC allows removal by adsorption of the more persistent trace pollutants (e.g., carbamazepine), and finally, sorption of the more lipophilic substances (e.g., musk fragrances) on the sludge will increase due to the development of agglomerates (flocs) that are smaller than those growing in a CAS due to the presence of the ultrafiltration membrane. Furthermore, since it is a process with membranes, the retention of the PAC and of the sludge, and therefore of the sorbed compounds, is complete.</p><p id="p0011" num="0011">In this sense, the only patent documents that have been found focus on using activated carbon in membrane bioreactors for the purpose of protecting membranes against blocked pores (<patcit id="pcit0001" dnum="JP1284304A"><text>JP 1284304 A</text></patcit>) or for improving the efficiency of nitrogen and dissolved organic matter removal (<patcit id="pcit0002" dnum="KR20030097075A"><text>KR 20030097075 A</text></patcit>).<!-- EPO <DP n="5"> --></p><heading id="h0003"><b><u>Disclosure of the Invention</u></b></heading><p id="p0012" num="0012">The present invention relates to a process for the removal of contaminating pharmaceutical products present in wastewater.</p><p id="p0013" num="0013">The effluent to be treated consists of wastewater which is characterized by the presence of organic matter and nutrients with concentration ranges of 500-2000 mg COD/L, 10-100 mg N-NH<sub>4</sub>/L and 1-10 mg P-PO<sub>4</sub>/L. The concentrations of pharmaceutical products under consideration are in trace amounts, i.e., below 100 µg/L.</p><p id="p0014" num="0014"><figref idrefs="f0001">Figure 1</figref> (see "Description of the Drawing" section) depicts the configuration of the process which is formed by two units. The stream of wastewater to be treated is pumped from the receiving tank towards the first unit, the sequential bioreactor. This tank has been designed to work sequentially following a scheduled program of 6-hour cycles regulated with a timer, each of which comprises different phases: filling (3-10%), anoxic operation (20-30%), aerobic operation (60-70%), settling and effluent withdrawal (3-10%). Metabolic reactions (denitrification, oxidation of organic matter and nitrification) catalyzed by different populations of microorganisms that are present, as well as the removal of pharmaceutical pollutants with higher biodegradability potential, such as ibuprofen, will occur throughout each operating cycle. Other compounds with lower biodegradability but higher potential of interacting with sludge, such as the case of galaxolide, will be retained in the sludge that is present. Operating with sludge retention times longer than conventional systems favors this contact, thus improving subsequent degradation. Likewise, the process aims to maximize nitrification-denitrification since the generation of ammonia monooxygenase (AMO) enzyme by specific bacterial groups improves the removal of some pharmaceutical pollutants, as described in the "State of the Art" section.</p><p id="p0015" num="0015">The addition of PAC directly in the sequential reaction unit at concentration ranges of 0.5-2 g/L allows: a) increasing the removal of pharmaceutical pollutants up to values greater than 90%, being especially significant in the case of more persistent pollutants (low biodegradability and low interaction with sludge) as they become completely eliminated; b) improving nitrification and denitrification which results in a higher production of the AMO enzyme; c) improving operation of the overall system by minimizing the problems of membrane fouling in the ultrafiltration membrane unit.<!-- EPO <DP n="6"> --></p><p id="p0016" num="0016">Once the operating cycle in the sequential unit is completed and the clarified effluent is obtained by settling the biomass that is present, the supernatant is partially drained out by means of a pump into the chamber containing the membrane, where an ultrafiltration membrane unit (pore size 0.04-0.4 µm) allows obtaining the final effluent of the process. The membrane operation follows a cycle comprising a suction period followed by another relaxation or backwash period taking up 80-90% and 10-20% of the operating time, respectively. Unlike the sequential reaction unit, in this second chamber an aeration stream from the lower area is maintained continuously to minimize membrane fouling. Two streams are obtained from this chamber: a) the final effluent of the process with a very low solid, organic matter and nutrient content, and with almost complete absence of pharmaceutical products, and b) a lower stream which contains a large amount of solids, and which is recirculated towards the sequential reaction unit. The purge is obtained from this recirculation stream, determining the residence time of the solids that are present (biomass and PAC), which will be between 30 and 120 days, whereas the HRT will be the usual residence time (6-24 hours) depending on the desired removal of conventional pollutants.</p><p id="p0017" num="0017">Unlike conventional processes, this process is designed for operating with very long SRTs, high biomass concentrations, microbial diversity, high enzymatic activity, etc., in order to maximize the removal of biodegradable and lipophilic pharmaceutical compounds and to achieve a very good quality final effluent in terms of its conventional (solids, organic matter and nutrients) and pharmaceutical pollutants levels. However, the strategy of adding PAC is key to achieve complete removal of pharmaceutical compounds, especially in relation to those persistent compounds for which the biodegradation or interaction of which with sludge is not very significant (for example, in the case of carbamazepine and diazepam, among others). Table 1 shows the efficiencies achieved in this process which are much greater than those usually indicated in conventional treatment systems.<!-- EPO <DP n="7"> -->
<tables id="tabl0001" num="0001"><table frame="topbot"><title>Table 1. Comparison between the removal efficiencies of the pharmaceutical compounds under consideration.</title><tgroup cols="3" colsep="0"><colspec colnum="1" colname="col1" colwidth="56mm"/><colspec colnum="2" colname="col2" colwidth="55mm"/><colspec colnum="3" colname="col3" colwidth="55mm"/><thead><row><entry valign="top">Compound</entry><entry align="center" valign="top">Removals in conventional systems (%)</entry><entry align="center" valign="top">Removals in the proposed process (%)</entry></row></thead><tbody><row><entry>Carbamazepine</entry><entry align="center">&lt; 20</entry><entry align="center">&gt; 99</entry></row><row><entry>Diazepam</entry><entry align="center">&lt; 20</entry><entry align="center">85-99</entry></row><row><entry>Diclofenac</entry><entry align="center">&lt; 40</entry><entry align="center">90-93</entry></row><row><entry>Fluoxetine</entry><entry align="center">70-85</entry><entry align="center">97-98</entry></row><row><entry>Naproxen</entry><entry align="center">&gt; 80</entry><entry align="center">90-93</entry></row><row><entry>Ibuprofen</entry><entry align="center">&gt; 90</entry><entry align="center">98-99</entry></row><row><entry>Sulfamethoxazole</entry><entry align="center">40-70</entry><entry align="center">97-99</entry></row><row><entry>Roxithromycin</entry><entry align="center">65-85</entry><entry align="center">97-99</entry></row><row><entry>Trimethoprim</entry><entry align="center">35-75</entry><entry align="center">90-99</entry></row><row><entry>Erythromycin</entry><entry align="center">50-75</entry><entry align="center">94-99</entry></row><row><entry>Galaxolide</entry><entry align="center">50-75</entry><entry align="center">86-93</entry></row><row><entry>Tonalide</entry><entry align="center">50-75</entry><entry align="center">80-87</entry></row><row><entry>Celestolide</entry><entry align="center">50-75</entry><entry align="center">86-97</entry></row></tbody></tgroup></table></tables></p><heading id="h0004"><b><u>Description of the Drawing</u></b></heading><p id="p0018" num="0018"><figref idrefs="f0001">Figure 1</figref> complements the description and allows a better understanding of the main technical features of the invention. This scheme has an illustrative and non-limiting nature. The different units comprised by the described process are shown.
<ul><li><figref idrefs="f0001">Figure 1</figref>.
<ul><li>1. Wastewater receiving tank</li><li>2. Sequential bioreactor</li><li>3. Unit containing ultrafiltration membrane</li><li>4. Inlet feeding of raw wastewater</li><li>5. Final effluent of treated water (permeate of the membrane unit)</li><li>6. PAC Addition</li><li>7. Recirculation pump</li><li>8. Raw wastewater feeding pump<!-- EPO <DP n="8"> --></li><li>9. Membrane unit permeate pump</li><li>10. Purge</li><li>11. Programmer-controlled automatic valve</li><li>12. Programmer</li><li>13. Air compressor</li><li>14. Valve</li><li>15. Stirrer motor</li><li>16. Stirrer blades</li><li>17. Ultrafiltration membrane unit</li></ul></li></ul></p><heading id="h0005"><b><u>Implementing Example</u></b></heading><heading id="h0006"><u><b>Example</b> 1</u></heading><p id="p0019" num="0019">Treatment of wastewater with average characteristics of 1000 mg COD/L, 80 mg N-NH<sub>4</sub>/L, 8 mg P-PO<sub>4</sub>/L and a pharmaceutical compound concentration of 10 µg/L of anti-inflammatory compounds (ibuprofen, naproxen and diclofenac); 10 µg/L of antibiotics (sulfamethoxazole, trimethoprim, roxithromycin and erythromycin); 10 µg/L of antidepressant compound (fluoxetine); 20 µg/L of tranquilizer compound (diazepam) as well as anticonvulsant (carbamazepine); 40 µg/L of substances used in the formulation of cosmetics (galaxolide, tonalide and celestolide).</p><p id="p0020" num="0020">This wastewater is fed to the sequential biological reaction unit (useful volume of 30 L, hydraulic residence time of 1 day) where the various processes of removal occur to a greater extent. This unit operates discontinuously following a programming sequence alternating different periods throughout a complete operating cycle of 6 hours: filling (8 minutes), anoxic operation (93 minutes), aerobic operation (236 minutes), settling (15 minutes) and effluent withdrawal (8 minutes). The volume exchange ratio in this unit is 25%. The addition of 1000 mg/L of PAC (real density of 1.665 g/cm<sup>3</sup>, apparent density of 0.25 g/cm<sup>3</sup> and specific surface area of 328 m<sup>2</sup>/g) is performed directly in this unit. Once the operating cycle ends, the effluent generated is fed to the membrane chamber. The cycle was run with an ultrafiltration flat sheet membrane unit made of polymeric material (pore size of 0.4 µm, surface area of 0.126 m<sup>2</sup>, nominal flow of 20 L/m<sup>2</sup>h and permeability of 98.71 L/m<sup>2</sup>h bar). Operating with this membrane unit involves alternating suction and relaxation periods (6.25 minutes and 1.25<!-- EPO <DP n="9"> --> minutes, respectively), maintaining an air stream at all times by means of coarse bubble diffusers located in the lower portion of said chamber to create the cross-flow necessary for minimizing the membrane fouling.</p><p id="p0021" num="0021">After operating with a solid retention time of 90-100 days (when PAC saturation in terms of pharmaceuticals starts to be observed), the characteristics of the final effluent of the process can be summarized as: 95-99% organic matter removal, 70-80% N-NH<sub>4</sub> removal and about 80% P-PO<sub>4</sub> removal. According to the removal of the pharmaceutical compounds under consideration, three groups stand out in terms of their behavior:
<ul><li>Compounds with higher affinity for PAC which are not significantly eliminated in the absence of PAC: carbamazepine, trimethoprim, roxithromycin, erythromycin and fluoxetine, very high removals (97-99%) being achieved. The main characteristic that these compounds share is that all of them have a pKa between 7-10 and can therefore be moderately alkaline. Moreover, these compounds have amino groups within their molecular structures which can be partially protonated under neutral conditions. Therefore, the main mechanism of removal of these compounds in the process lies in their interaction with PAC.</li><li>Compounds with medium biodegradability such as ibuprofen and naproxen. These compounds have high percentages of removal (&gt; 90%), biodegradation being the main mechanism of removal, whereas adsorption in sludge or in PAC is not significant. However, the greater abundance of nitrifying organisms observed after the addition of PAC further improves their removal. The long SRT applied in the process and the development of a wide diversity of microorganisms are the main factors that would explain the removal of these substances.</li><li>Lipophilic compounds with low affinity for PAC and intermediate biodegradability such as galaxolide, tonalide and celestolide fragrances. Their removal does not increase significantly after the addition of PAC, basically being retained by the sludge (absorption in the lipophilic layer of cell walls). Once retained, these compounds can be biodegraded. The complete biomass retention in the process due to the presence of the ultrafiltration membrane unit assures the absence of these compounds in the final effluent.</li></ul></p></description><claims mxw-id="PCLM90460444" lang="EN" load-source="patent-office"><!-- EPO <DP n="10"> --><claim id="c-en-0001" num="0001"><claim-text>A process for the removal of pharmaceutical compounds present in wastewater by means of using powdered activated carbon (PAC) in a sequential bioreactor coupled to a chamber containing ultrafiltration membranes comprising the following steps:
<claim-text>a) Collecting wastewater which is <b>characterized by</b> the presence of organic matter in the range of 500-2000 mg COD/L, ammonia in the range of 10-100 mg N-NH<sub>4</sub>/L and phosphorus in the range of 1-10 mg P-PO<sub>4</sub>/L, as well as of pharmaceutical compounds in trace concentrations: below 100 µg/L.</claim-text>
<claim-text>b) Biological treatment of wastewater in a sequential batch reactor receiving a direct feeding of powdered activated carbon for the purpose of maintaining a constant concentration in the range of 0.5-2 g PAC/L that will be achieved by means of regulating the purge flow rate (maintaining a solid retention time of 30-120 days), where the operation of the sequential batch reactor involves monitoring by means of a timer a 6-hour controlled program cycle comprising the following phases: 3-10% partial filling; 20-30% under anoxic reaction conditions, without aeration but with stirring; 60-70% under aerobic reaction conditions, with aeration; and 3-10% settling and partial draining, with a volumetric exchange in the range of 20-50%.</claim-text>
<claim-text>c) Treatment of the effluent generated after the partial draining of the sequential batch reactor in a contiguous chamber having immersed therein an ultrafiltration membrane, which has a pore size of 0.04-0.4 µm and operates following a continuous routine alternating suction and relaxation periods taking up 80-90% and 10-20% of the operating time of the membrane, respectively, and a continuous aeration from the bottom, for which there are arranged coarse bubble diffusers continuously injecting an air stream for obtaining a cross-flow on the surface of the membrane in order to minimize membrane fouling, in which two streams are produced: i) a permeate generated by the membrane constituting the final stream of the process, ii) a stream containing the reject accumulated in this chamber, a portion of which is recirculated by means of a pump into the sequential batch reactor during the aeration phase and the other portion constitutes the purge of the process.</claim-text><!-- EPO <DP n="11"> --></claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The process according to claim 1 for the removal of pharmaceutical compounds present in wastewater from hospitals, pharmaceutical industries and/or farming and stock raising using medicaments for veterinary use.</claim-text></claim></claims><drawings mxw-id="PDW20423079" load-source="patent-office"><!-- EPO <DP n="12"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="142" he="108" img-content="drawing" img-format="tif"/></figure></drawings><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="157" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="158" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="157" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
